Skip to main content

Table 1 Baseline characteristics

From: Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study

  Vemurafenib (N = 46)
Age, y, median (range) 42 (19–69)
Male, n (%) 21 (46)
ECOG performance status, n (%)
 0 30 (65)
 1 16 (35)
Serum LDH level, n (%)
 Normal 27 (59)
 Elevated 19 (41)
Histologic subtype, n (%)
 Acral lentiginous 1 (2)
 Nodular 7 (15)
 Pigmented nevus 1 (2)
 Superficial spreading 14 (30)
 Unknown 23 (50)
Median time since diagnosis of metastatic disease (range), months 4.5 (0–31.0)
Disease stage, n (%)
 Unresectable stage IIIC 3 (7)
 Stage IV 43 (94)
  M1aa 9 (21)
  M1ba 8 (19)
  M1ca 26 (61)
Prior treatment for metastatic disease, n (%) 31 (67)
Number of prior therapies for metastatic disease, n (%)
 0 15 (33)
 1 21 (46)
 2 6 (13.0)
  ≥ 3 3 (7)
 Unknown 1 (2)
Previous CTLA-4 or PD-1/PD-L1 inhibitor, n (%) 0 (0)
  1. ECOG Eastern Cooperative Oncology Group, LDH lactate dehydrogenase; CTLA-4 cytotoxic T-lymphocyte-associated protein 4; PD-1 programmed death 1; PD-L1 programmed death ligand 1
  2. aDenominator is the number of patients with stage IV disease (n = 43)